Grail
Wolfe Research Initiates Coverage of Grail With Peer Perform, Veracyte With Outperform Rating
Grail's flagship product, Galleri, detects more than 50 types of cancer, while Veracyte offers tests intended to personalize treatment for thyroid, breast, and lung cancer.
Grail Q3 Revenues Rise 39 Percent
Grail reported that strong sales of its blood-based Galleri cancer early detection test drove revenue growth in its first operating quarter as a public company.
Researchers Stress Specificity of Grail Multi-Cancer Detection Test in Response to Study Criticism
Premium
The authors of a commentary said they view recent study results as informative, though limited, regarding the test's performance in prostate cancer.
Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.
Illumina Wins Jurisdictional Appeal in Europe Over Grail Deal, Dodges €432M Fine
In its decision, the European Court of Justice also ordered the European Commission to pay legal costs incurred by Illumina and Grail.